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Aims: Carefully designed and established biobanks are considered one of the most essential 
resources to foster biomedical research as they provide cost-effective and rapid access to a 
vast variety of biological materials and related anthropometrics allowing for testing of various 
biomarkers as well as numerous original and pertinent bioclinical hypotheses related to human 
disease etiology and prognosis. The objective of the present study was to present the baseline 
data, design, and methods used for the establishment of the Vejle Diabetes Biobank. Further 
aims included assessment of the prevalence of diabetes and quality of diabetes treatment in a 
specified Danish region.
Methods: The Vejle Diabetes Biobank was established from 2007 to 2010 as a regional Bio-
bank containing blood, DNA, and urine samples from patients with diabetes and a gender- and 
age-matched control population aged 25–75 years. Anthropometrics were obtained by physical 
examination, questionnaires, and interviews at the time of inclusion into the Biobank. The cohort 
was linked to the Danish Civil Registration System, the Danish National Patient Registry, and 
the Danish National Prescription Registry.
Results: In total, 4,255 nondiabetic individuals and 3,320 patients with diabetes were included. 
Type 2 diabetes (T2D) patients had a higher body mass index (30 kg/m2) than type 1 diabetes 
(T1D) patients (25 and 26 kg/m2 in women and men, respectively) and control subjects (25 and 
27 kg/m2 in women and men, respectively). Fasting levels of plasma triglycerides and blood 
pressure were higher in T2D patients (1.5 mmol/L and 148/85 mmHg, respectively) compared 
with T1D patients (0.9 mmol/L and 139/81 mmHg, respectively), whereas glycated hemoglobin 
(HbA1c), plasma high density lipoprotein, low density lipoprotein, and total cholesterol were 
lower in T2D patients (51 mmol/mol, 1.2 mmol/L, 2.2 mmol/L, and 4.2 mmol/L, respectively) 
compared with findings in T1D patients (61 mmol/mol, 1.6 mmol/L, 2.3 mmol/L, and 4.4 
mmol/L, respectively). At the time of inclusion into the Biobank, 56% of the T2D patients 
and 25% of T1D patients had an HbA1c <7% (53 mmol/mol). Only 28% and 34% of the T2D 
patients, respectively, reached treatment target for blood pressure and lipids.
Conclusion: The Vejle Diabetes Biobank represents one of the largest open diabetes case-control 
cohorts in Denmark. The Biobank invites collaborative investigations of diabetes and diabetes 
complication etiologies as well as studies of prognostic or predictive biomarkers.
Keywords: diabetes, type 2 diabetes, HbA1c, diabetes Biobank resource, research database
Background
Biobanks have become one of the most valuable resources in biomedical research1 as 
they provide cost-effective and rapid access to a vast spectrum of biological materi-
als and related anthropometric data allowing for comprehensive studies, often to be 
shared by multiple research environments. Recently, a Canadian study2 suggested that 
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biorepositories coordinating the activity of biobanking “rank 
among the most important of established health research 
infrastructures as contributors to research publications.” Bio-
banking of human biological materials together with relevant 
coupling to national disease and mortality registries enable 
longitudinal follow-up, improved opportunity of understand-
ing disease mechanism, and contribute to documentation of 
quality and lifelong patient outcomes.
The primary objective for establishing the Vejle Diabetes 
Biobank was to enable the investigation of prognostic and 
predictive values of a variety of possible etiological compo-
nents. Further, to investigate the prognostic and predictive 
value of biomarkers for development of diabetes, its associ-
ated complications, and outcomes. Repeated data analyses 
were performed during follow-up on patients with time.
The objective of the present study is to present the base-
line data, design, and methods used for the establishment of 
the Vejle Diabetes Biobank and provide information about the 
quality of diabetes patient treatment at the time of the estab-
lishment of the Biobank with the ultimate goal of providing 
information about the resource for national and international 
investigators in this research field.
Materials and methods
Recruitment of study participants
The Vejle Diabetes Biobank was established as a regional 
Biobank containing blood and urine samples from individuals 
with diabetes and a gender- and age-matched control popula-
tion aged between 25 and 75 years (both ages included) as 
of the inclusion date per December 31, 2006.
Subjects eligible for the cohort were identified using 
information from the Civil Registration System.3,4 The 
identified diabetes and control populations were limited to 
individuals who were alive and residing in the former County 
of Vejle area on December 31, 2006. These eligible individu-
als received an information letter asking them to participate 
in the Biobank as diabetes or control subjects, respectively. 
In case of not responding, an information letter was sent as 
a reminder. The subjects participating were not given any 
compensation for their donation of blood and urine.
Individuals who responded positively subsequently 
received a questionnaire (Supplementary material) to fill in 
at home and were given an appointment at one out of four 
hospitals in the predefined region of Denmark (Vejle, Kolding, 
Fredericia, and Horsens) for anthropometric examinations 
and biological sampling. The participants were asked to fast 
overnight from 10 p.m. and to abstain from physical activity 
72 hours before their appointment for entering the Biobank. 
They were examined by laboratory technicians or healthcare 
assistants at the respective hospital and the completed ques-
tionnaire was reviewed together with the participant. The 
patients’ verification of the diabetes diagnosis was considered 
the gold standard;5 thus, only subjects acknowledging having 
diabetes were included in the diabetes cohort. The participants 
requested as control individuals were likewise asked if they 
acknowledged not having diabetes. Only subjects acknowl-
edging no diabetes were included in the control cohort.
The inclusion and exclusion criteria for 
the diabetic cohort
The patients with diabetes were identified by the following 
inclusion criteria of which at least one criteria had to be met: 
A) At least one glycated hemoglobin (HbA1c) value ≥6.6% 
(≥48.6 mmol/mol) registered in the Clinical Laboratory 
Information System (LABKA),6 in the period from January 
1996 to December 2006. B) At least three HbA1c values 
<6.6% (48.6 mmol/mol) registered in LABKA in the period 
from January 2002 to December 2006. C) Patients registered 
in the Danish National Prescription Registry7 with at least 
one prescription handled in the former County of Vejle in 
the period from January 1, 2006 to December 31, 2006 
for oral antidiabetic agents or insulin with the Anatomical 
Therapeutic Chemical (ATC) Classification System8 code 
A10A (insulin) and/or A10B (oral antidiabetic agents). D) All 
patients registered in the Danish National Patient Registry9 
with a contact (inpatient- or outpatient-based) in the period 
from 1977 to December 200610 at hospitals in the former 
County of Vejle with a diabetes diagnosis (both primary 
and secondary diagnoses) (International Classification of 
Diseases [ICD] code 250 [Eighth Revision] and/or codes 
DE10 and/or DE11 [Tenth Revision] [ICD10], which is in 
use since 1994 in Denmark).11
Based on the above-mentioned four criteria, the eligible 
study participants for the diabetes sample comprised of 14,831 
patients who potentially might suffer from diabetes, of whom 
3,345 were excluded due to age under 25 or age above 75 years.
In order to minimize the enrolment of individuals with a 
different genetic background than Danish, individuals with 
a non-Danish first name and/or last name were not asked to 
participate in the Biobank (n=647 corresponding to 6% of 
the diabetic population selected). Detailed information on 
the inclusion of diabetes patients is given in flow diagram 1 
(Figure 1). In total, 10,408 potential diabetic individuals were 
asked to participate in the Vejle Diabetes Biobank, whereof 
4,174 responded positively (response rate of 40%). In total, 
3,320 individuals consented to join the Vejle Diabetes Biobank 
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Figure 1 Selection of patients with diabetes for the Vejle Diabetes Biobank.
Abbreviations: ATC, Anatomical Therapeutic Chemical; ICD, International Classification of Diseases; T1D, type 1 diabetes; T2D, type 2 diabetes; HbA1c, glycated 
hemoglobin.
Criteria A Criteria B Criteria C Criteria D
Search
criteria
Patients registered with
minimum one HbA1c
value ≥6.6% (48.6
mmol/mol) in the
laboratory database
Patients registered with
minimum three HbA1c
values <6.6% (48.6
mmol/mol) in the
laboratory database
Patients registered with
minimum one
prescription for oral anti-
diabetic agents (ATC
code A10B) or insulin
(ATC code A10A) in the
Danish National
Prescription Registry
(January 1, 2006–
December 31, 2006)
All patients registered in
the Danish National
Patient Registry with a
contact at hospitals in the
former county of Vejle
with a diabetes diagnosis
ICD code 250 (Eighth
Revision) or code DE10
and/or DE11 (Tenth
Revision)
(1977–2006)
(2002–2006)(1996–2006) or or or
14,831 potential patients with diabetes alive in the former Vejle county on December 31, 2006
N=1,486 potential patients with diabetes alive in the former Vejle county aged ≥25 and ≤75 years on December 31, 2006
N=10,408 potential patients with diabetes alive in the former Vejle county aged ≥25 and ≤75 years, not emigrated or deceased
after December 31, 2006 and having a Danish first and last name were to participate in Vejle Diabetes Biobank
N=3,345 potential patients with diabetes
aged <25 or >75 years in the former Vejle
county on December 31, 2006 excluded 
N=1,078 individuals with non-Danish 
first name or last name as well as deceased
or emigrated after December 31, 2006
excluded 
N=6,234 nonresponders
N=4,174 responders
N=854 responders not acknowledging
having diabetes excluded
N=3,320 responders acknowledging having diabetes, accepted participating in Vejle diabetes cohort
N=2,721 T2D N=599 T1D
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as patients with diabetes. The patients were classified accord-
ing to their own statement as either type 1 diabetes (T1D) 
or type 2 diabetes (T2D) patients as previously validated by 
Kristensen et al.5 Patients who did not have knowledge of 
their own classification (~2%) were stratified based on the 
following criteria for T2D and T1D, respectively; T2D: dia-
betes debut after the age of 30 years and treatment with oral 
antidiabetic agents (ATC Classification System code A10B) 
for at least 1 year following time of diagnosis and/or dietary 
treatment after diagnosis, and T1D: treatment with insulin or 
insulin analogues from time of diagnosis (ATC Classification 
System code A10A) without any oral antidiabetic agents (ATC 
Classification System code A10B). According to the above 
stated criteria, 599 patients were classified as T1D patients 
and 2,721 patients were classified as T2D patients (Figure 1).
Inclusion and exclusion criteria for 
individuals in the control cohort
The individuals for the control cohort were selected by the 
Danish Civil Registration System from the background popu-
lation of the former County of Vejle, Denmark (n=360,921). 
Planned sampling was 1:1.
All citizens of the County of Vejle aged ≥25 and ≤75 
years (n=229,551) and alive at the inclusion date December 
31, 2006 were divided into 10-year age intervals in order to 
obtain a random control from the background population, 
and gender-matched to the diabetes population, subsequently 
randomly selected. Of the 11,065 control subjects who 
received a request to participate in the Biobank, 4,290 chose 
to participate (response rate of 39%). Thirty-five subjects 
who did not fulfill any of the four diabetes criteria A–D but 
acknowledged having diabetes were excluded from the con-
trol population. In total, the control population constituted of 
4,255 individuals without diabetes. Detailed information on 
the inclusion of the control persons is given in flow diagram 
2 (Figure 2).
Anthropometrics
The following anthropometrics were examined during the 
visit at the enrolment in the Vejle Diabetes Biobank: height 
(ultrasound height rod, Soehnle Industrial Solutions GmbH, 
Backnang, Germany), weight with indoor clothes but with-
out shoes, body mass index (BMI) calculated by dividing 
weight in kilograms by the squared height in meters,12 body 
fat percentage (Tanita Body Composition Analyzer 418, IL, 
USA), waist and hip circumference was measured according 
to World Health Organization standard,13 and systolic and 
diastolic blood pressures were measured after 5 minutes rest 
in sitting position (Omron M5 Professional, Osaka, Japan).
The following information was obtained through the 
questionnaire: smoking status (daily, occasionally, former-
smoker, ever-smoker), alcohol consumption (none, occasion-
ally, 1–7 units per week, 7–14 units per week, 14–21 units per 
week, more than 21 units per week), exercise habit (no, yes; if 
yes: number of times per week, number of minutes per time; 
low intensity, moderate intensity, high intensity), gestational 
diabetes (yes, no), age at onset of diabetes, heart diseases (eg, 
acute myocardial infarction, angina pectoris, congestive heart 
failure), cerebral diseases (eg, stroke), late diabetic complica-
tions: eyes, kidneys, nerves, foot ulcers (yes, no, not known), 
diabetes in parents/siblings and/or children (yes, no), diabe-
tes medication (insulin, glucagon-like peptide 1 analogues/
dipeptidyl peptidase IV inhibitors, biguanides [metformin] 
alone or in drug combinations, β-cell stimulating drugs [ie, 
sulfonylurea and meglitinides], alpha-glucosidase inhibi-
tors, glitazones), and other medication (cholesterol-lowering 
agents, anticoagulants, antihypertensive drugs (angiotensin 
converting enzyme [ACE]-inhibitors, angiotensin 2 receptor 
[AT2]-antagonists, β-blockers, calcium antagonists, renin-
inhibitors, diuretics, other).14
Advocating and advertising for participating in the 
 biobank were repeatedly done in the local media and infor-
mation flyers were distributed at the general practitioners in 
the local area and the outpatient clinics at the four hospitals 
participating in the recruitment as an attempt to improve the 
response rate.
Biological sample collection and storage 
conditions
In the period from March 1, 2007 to May 1, 2010, blood (125 
mL) and urine (10 mL, first-morning urine sample brought by 
the participant) samples were collected from each participant 
at attendance and plasma, serum, and buffy coat were sepa-
rated, aliquoted, and stored at –80°C until analysis.14 In total, 
for every subject, 56 tubes of serum, ethylenediaminetet-
raacetic acid (EDTA)- and Li-heparin plasma, EDTA whole 
blood, and buffy coat were stored centrally at Vejle Hospital.
Blood samples were analyzed for HbA1c, fasting plasma 
glucose (FPG), C-peptide, triglycerides, total cholesterol, high 
and low density lipoproteins (HDL, LDL), middle sensitive 
CRP (measurable down to 0.3 mg/L), p-albumin, calcium, 
alanine aminotransferase (ALAT), and p-creatinine. Due to 
financial restrictions, ALAT and p-creatinine in the control 
population were analyzed in February 2016 on Cobas 8000 
(Hoffmann-La Roche Ltd., Basel, Switzerland), whereas in the 
diabetes population it was analyzed in 2009–2010 on a Modu-
lar P system (Hoffmann-La Roche Ltd.). Urine samples in the 
diabetes cohort were analyzed for U-albumin, U-creatinine, 
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Figure 2 Selection of participants without diabetes for the Vejle Diabetes Biobank.
N=360,921 inhabitants in former Vejle county, December 31, 2006
N=229,551 inhabitants in former Vejle county aged ≥25 and ≤75 years on December 31, 2006
N=12,280 women and men in former Vejle county aged ≥25 and ≤75 years 
on December 31, 2006
N=11,217 women and men in former Vejle county aged ≥25 and ≤75 years, not fulfilling the criteria A–D, not self- 
enrolled, on December 31, 2006
N=11,065 women and men in former Vejle county aged ≥25 and ≤75 years, not fulfilling the criteria A–D, not self- 
enrolled, not emigrated, or deceased and having a Danish first and last name on December 31, 2006, were asked to participate
N=131,370 inhabitants aged <25 or >75
years in the former Vejle county on December
31, 2006 excluded 
N=4,290 responders N=6,775 nonresponders
N=4,255 registered as
control individuals
N=35 individuals
acknowledging having
diabetes excluded
Divided into 10-year intervals and gender
matched to the diabetes population,
subsequently randomly selected
N=1,063 patients with diabetes
fulfilling the criteria A–D and self-
enrolled individuals without diabetes
excluded
N=152 individuals with a non-
Danish first name or last name as
well as deceased or emigrated after
December 31, 2006 excluded
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U-protein, and U-albumin/creatinine ratio. GFR was estimated 
by the use of the CKD-EPI equation.15
Venous blood for FPG measurements was drawn from an 
antecubital vein in tubes containing Li-heparin (Venosafe®, 
Terumo Europe NV, Leuven, Belgium). The samples were 
immediately cooled in ice water, centrifuged at 5°C at 3,000× 
g for 10 minutes, and plasma separated within 30 minutes.16 
Aliquots of plasma were stored at –80°C until analysis. Glu-
cose measurements as well as triglycerides, total cholesterol, 
HDL, LDL, CRP, p-albumin, calcium, ALAT, p-creatinine, 
U-albumin, U-creatinine, U-protein, and U-albumin/creati-
nine ratio were performed on a Modular P system (Hoffmann-
La Roche Ltd.). Total imprecision and analytical bias were 
controlled by external HK1 control material purchased from 
the Danish Institute for External Quality Assurance for Labo-
ratories in Health Care, Glostrup, Denmark.17 The analyses 
performed in the laboratory fulfilled the generally accepted 
criteria for bias and coefficient of variation.18,19
All samples were thawed in an incubator until reaching 
a temperature of 37°C, then mixed by vortexing and centri-
fuged at 2,000× g for 10 minutes before analyzing. Whole 
blood samples for HbA1c measurements were drawn from the 
same puncture as for FPG analysis. Samples were collected in 
tubes containing EDTA (K3E, Venosafe) and stored at –80°C 
until analysis.14 HbA1c analysis was carried out on a fully 
automated glycohemoglobin analyzer (Tosoh HLC-723 G7, 
Tosoh, Tessenderlo, Belgium) with total analytical imprecision 
<1.8% Diabetes Control and Complication Trial (DCCT) in 
the range 5.0–9.0 HbA1c%, corresponding to <2.7% Interna-
tional Federation of Clinical Chemistry (IFCC) in the range 
31–75 mmol/mol.16 Analytical bias was assessed by external 
control materials (no. 3044 F1) from Labquality20 and in the 
analyzing period positive bias was measured below 3.5% in 
the range 5.0%–9.0% in DCCT units (below 5.2% IFCC in 
the range 31–75 mmol/mol), which was acceptable according 
to the DCCT/National Glycohemoglobin Standardization Pro-
gram criteria.21 C-peptide was analyzed on an Advia Centaur 
System (Siemens Healthineers, Erlangen, Germany).
Sample size and selection considerations
The goal of the establishment of the Vejle Diabetes Biobank 
was to include all patients with T2D aged between 25 and 
75 years in the former Vejle County. All patients with possible 
diabetes were thus primarily elected. For case-control geno-
typing studies, statistical power calculation demonstrated 
a power allowing for the detection of common genetic risk 
variants with an allele frequency of >10% with a relative risk 
(RR) of 1.3 based on the inclusion of 1,000 patients with 
T2D (cases) and 1,000 control persons. At allele frequency 
of >35% in the same setup, the calculation demonstrated a 
statistical power of 80% for the identification of genetic risk 
variants with an RR of 1.2. In this study having more than 
2,000 cases and over 4,000 controls, a statistical power of 
80% will allow for identification of genetic risk variants with 
an allele frequency of >8% with an RR of 1.3.
Follow-up
The prospect of the Biobank was estimated to 10–15 years 
with consecutive follow-up data analysis on the existing data 
without repeated sampling.
Data sources
The cohort was linked to the Danish Civil Registration 
System3,4 and the Danish National Patient Registry9 in 
2011 and again in August 2015. Since the establishment in 
1968, the Civil Registration System identifies all living and 
deceased persons in Denmark by using the Danish Personal 
Identification Number. This is a 10-digit number unique for 
every citizen4 and used for all purposes involving health 
care, social, and administrative transactions. The Danish 
Civil Registration System provides information about vital 
status, emigration, or in case of deceased subjects the date 
of death, whereas the Danish National Patient Registry con-
tains records of all hospital contacts (in- and outpatient) and 
ICD8 and ICD10 diagnostic codes.10,22 The Danish National 
 Prescription Registry7 was accessed in the initial phase in 
order to find patients registered with at least one prescription 
in the period from January 1, 2006 to December 31, 2006 for 
oral antidiabetic agents or insulin. LABKA was accessed in 
order to obtain the laboratory data produced.
Validation of the anthropometrics
Data were visualized by graphic presentation and checked 
for reliability and consistency. Flawed data were corrected 
according to primary data source.
Treatment goals
The latest recommended target for glycemic regulation in 
nonpregnant adults with diabetes is HbA1c <7.0% (53 mmol/
mol), although it is recognized that some diabetes patients may 
benefit from less strict control (HbA1c <7.5%–8.0%, 58–64 
mmol/mol) and others from a more rigorous control (HbA1c 
<6.0%–6.5%, 42–48 mmol/mol).23–27 For these reasons, the 
analyses of the diabetes cohort at several HbA1c limits were 
done. For comparison over time, the authors also did the 
analysis with a target limit for normalization of HbA1c of 
6.6% (48.6 mmol/mol) corresponding to the 99.9 percentile 
limit in a nondiabetic population in the former Vejle County 
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as previously documented.28 This limit was also used in the 
inclusion criteria A and B for the diabetes population.
Regarding hypertension, it is recommended to maintain 
the systolic blood pressure below 140 mmHg and the dia-
stolic blood pressure below 90 mmHg.29 The guidelines on 
antihypertensive treatment in diabetes patients recommend 
either an ACE-inhibitor or AT2 antagonist as first choice.
In managing the dyslipidemia closely related to T2D, it is 
recommended to treat patients aged ≥40 years with statins, 
dosage dependent on the presence of cardiovascular disease 
risk factors.29 The targets are triglycerides <1.7 mmol/L (150 
mg/dL), LDL <2.6 mmol/L (100 mg/dL), HDL ≥1.0 mmol/L 
(40 mg/dL) for men and ≥1.3 mmol/L (50 mg/dL) for women, 
and total cholesterol <4.5 mmol/L.
Statistical methods
Normally distributed data are presented as mean ± standard 
deviation; nonparametric data are presented as median and 
25–75 percentiles. For the statistical analyses, SPSS  version 23 
(IBM Corporation, Armonk, NY, USA) and the R project for 
statistical programming (R version 3.2.3) were used.
Ethics
The study was approved by the Danish Data Protection 
Agency (j. no. 2006-53-1385 and j. no. 2008-58-0035) and 
by The Regional Scientific Ethical Committees for Southern 
Denmark (j. no. S-20080097).
Results
In total, 4,255 control persons with no diabetes and 3,320 
patients with diabetes, hereof  2,721 T2D patients and 599 T1D 
patients, were included from March 1, 2007 to May 1, 2010.
Anthropometrics and biochemistry
The baseline characteristics of the study participants in the 
Vejle Diabetes Biobank are described in Table 1. It is evident 
Table 1 Baseline characteristics of the study population in the Vejle Diabetes Biobank
Variable
Median (25–75 quartiles) unless stated 
otherwise
Type 2 diabetes 
(T2D) patients
Type 1 diabetes 
(T1D) patients
Control population Missing na (T2D/
T1D/control 
population)
Enrolled, n 2,721 599 4,255
Sex, n (%)
Female
Male
1,052 (39)
1,669 (61)
234 (39)
365 (61)
1,873 (44)
2,382 (56)
Age, December 31, 2006 (years) 62 (56–68) 51 (41–61) 59 (51–65)
Age at time of diagnosis (years) 56 (49–62) 30 (17–42) Not relevant 202/27
Median years diagnosed (years) 4 (1–8) 18 (9–29) Not relevant 202/27
Height (cm)
Women
Men
162 (158–167)
175 (171–179)
166 (162–170)
178 (173–181)
165 (160–169)
177 (172–180)
1/0/0
1/1/0
Weight (kg)
Women
Men
80 (71–93)
91 (82–103)
68 (60–77)
80 (72–90)
67 (60–77)
83 (75–92)
6/0/1
2/1/2
BMI (kg/m2)
Women
Men
30 (27–35)
30 (27–33)
25 (22–28)
26 (23–28)
25 (22–28)
27 (25–29)
6/0/1
2/1/2
Waist (cm)
Women
Men
101 (93–111)
106 (98–115)
84 (79–94)
93 (87–101)
85 (77–93)
97 (91–104)
3/2/0
4/2/1
Hip (cm)
Women
Men
109 (102–118)
106 (101–112)
100 (93–107)
100 (96–105)
98 (92–105)
101 (97–106)
4/4/0
4/1/2
Waist–hip ratio
Women
Men
0.92 (0.87–0.96)
0.99 (0.96–1.03)
0.86 (0.82–0.90)
0.94 (0.89–0.99)
0.87 (0.82–0.91)
0.96 (0.93–1.00)
4/4/0
4/2/2
Blood pressure (mmHg)
Systolic
Diastolic
148 (136–162)
85 (79–92)
139 (127–154)
81 (74–88)
142 (128–157)
86 (79–94)
29/10/33
31/10/33
Glycemic parameters
HbA1cb (mmol/mol)
HbA1c (%)
Fasting plasma glucose (mmol/L)
C-peptide (pmol/L)
51 (45–58)
6.8 (6.3–7.5)
8.1 (7.0–9.6)
677 (450–904)
61 (53–68)
7.7 (7.0–8.4)
9.4 (6.8–13.1)
10 (10–102)
37 (34–39)
5.5 (5.3–5.7)
5.6 (5.2–5.9)
453 (346–628)
11/2/4
11/2/4
9/0/17
43/14/140
(Continued )
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Table 1 (Continued )
Variable
Median (25–75 quartiles) unless stated 
otherwise
Type 2 diabetes 
(T2D) patients
Type 1 diabetes 
(T1D) patients
Control population Missing na (T2D/
T1D/control 
population)
Lipids (mmol/L)
Total cholesterol 
LDL
HDL
Triglycerides
4.2 (3.7–4.8)
2.2 (1.8–2.7)
1.2 (1.0–1.5)
1.5 (1.1–2.2)
4.4 (3.9–4.9)
2.3 (3.9–4.9)
1.6 (1.3–1.9)
0.9 (0.7–1.3)
5.3 (4.6–6.0)
3.2 (2.6–3.8)
1.5 (1.2–1.8)
1.1 (0.8–1.5)
9/1/15
9/2/15
9/0/15
9/0/15
CRP (mg/L) (ref. <6) 1.9 (0.9–4.2) 1.2 (0.5–2.6) 1.3 (0.6–2.8) 9/0/17
Calcium (mmol/L) 2.29 (2.24–2.35) 2.27 (2.20–2.33) 2.26 (2.20–2.31) 9/0/16
ALAT (U/L)
Women (ref. 10–45)
Men (ref. 10–70)
23 (18–32)
27 (20–38)
20 (15–25)
24 (18–32)
20 (16–27)
26 (21–37)
10/3/19
20/1/30
P-albumin (g/L) 45 (44–47) 44 (43–46) 45 (43–46) 9/0/17
Renal parameters
P-creatinine (µmol/L) 
Women (ref. 45–90)
Men (ref. 60–105)
eGFRc (mL/min/1.73 m2)
U-albumin (mg/L)
U-creatinine (µmol/L)
U-albumin/creatinine ratio (mg/g)
68 (60–79)
84 (75–96)
83 (70–94)
7 (4–12)
8 (5–11)
9 (5–17)
68 (62–76)
82 (74–94)
92 (77–102)
7 (4–14)
7 (5–12)
8 (5–16)
74 (65–82)
91 (81–101)
78 (67–90)
n.a.
n.a.
n.a.
9/3/16
14/0/24
23/3/40
7/4/4,246
8/4/4,246
13/8/4,246
Smoking status, n (%)
Never
Former
Current
913 (34)
1,231 (45)
571 (21)
233 (39)
198 (33)
168 (28)
1,664 (39)
1,707 (40)
873 (21)
Antidiabetic treatment, n (%)
Oral exclusively
Insulin and oral
Insulin exclusively
None
1,535 (56)
289 (11)
305 (11)
592 (22)
8 (1)
22 (4)
455 (76)
114 (19) 4,255 (100)
Antihypertensive treatment, n (%)
ACE-inhibitorsd
AT2 antagonistse
Calcium blockers
β-Blockers
Diuretics
Renin inhibitors
2,136
1,122 (53)
704 (33)
776 (36)
7  8 (34)
1,192 (56)
8 (0.4)
329
204 (62)
113 (34)
133 (40)
88 (27)
178 (54)
1 (0.3)
1,172
349 (30)
245 (21)
397 (34)
381 (33)
603 (51)
1 (0.09)
Alcohol consumption
Women, n (%)
None
Occasionally
1–7 units/week
7–14 units/week
14–21 units/week
>21 units/week
Men, n (%)
None
Occasionally
1–7 units/week
7–14 units/week
14–21 units/week
>21 units/week
Lipid lowering medicationf, n (%)
≥40 years and on statins, n (%)
483 (46)
173 (16)
315 (30)
58 (6)
20 (2)
2 (0.2)
325 (19)
219 (13)
680 (41)
238 (14)
149 (9)
57 (3)
2004 (74)
1983 (74)
80 (34)
18 (8)
104 (44)
22 (9)
9 (4)
0 (0)
68 (19)
35 (10)
156 (43)
53 (15)
37 (10)
16 (4)
325 (54)
295 (63)
321 (17)
321 (17)
849 (45)
297 (16)
72 (4)
10 (0.5)
180 (8)
243 (10)
1,015 (43)
481 (20)
339 (14)
123 (5)
692 (16)
690 (17)
First-degree relative with diabetes, n (%) 1,300 (48) 233 (39) 908 (21)
Notes: aMissing numbers (n) for T2D/T1D/Control population, respectively, bHbA1c IFCC mmol/mol =10.93× HbA1c DCCT % – 23.54, ceGFR estimated by the use of 
the CKD-EPI equation, dAngiotensin-converting-enzyme inhibitors, eAngiotensin 2 receptor antagonists, fLipid-lowering medication: simvastatin, fibrates, and nicotinic acid.
Abbreviations: ALAT, alanine aminotransferase; BMI, body mass index; DCCT, Diabetes Control and Complication Trial; IFCC, International Federation of Clinical 
Chemistry; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1c, glycated hemoglobin; n.a., not available.
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that T2D patients were heavier and had a higher median BMI 
(30 and 30 kg/m2 in women and men, respectively) than T1D 
patients (25 and 26 kg/m2 in women and men, respectively) 
and control subjects (25 and 27 kg/m2 in women and men, 
respectively). Plasma triglycerides and blood pressure were 
higher in T2D patients (1.5 mmol/L and 148/85 mmHg, 
respectively) compared with T1D patients (0.9 mmol/L and 
139/81 mmHg, respectively), whereas plasma HDL was 
lower in T2D patients (1.2 mmol/L) than in T1D patients (1.6 
mmol/L). HbA1c was lower in T2D patients (51 mmol/mol) 
compared to T1D patients (61 mmol/mol); moreover, plasma 
LDL and total cholesterol levels were lower in T2D patients 
(2.2 and 4.2 mmol/L, respectively) compared to T1D patients 
(2.3 and 4.4 mmol/L). Plasma levels of CRP and ALAT in 
women were, despite being in normal range, elevated in T2D 
patients compared with both controls and T1D patients. The 
plasma concentration of ALAT in men was higher in T2D 
patients compared to T1D patients.
Quality of diabetes care
The distribution of patients fulfilling key quality criteria for 
diabetes treatment is demonstrated in Tables 2 and Table 3A, B. 
As shown in Table 2, 56% and 32% of patients with T2D, 
respectively, had HbA1c <7.0% and <6.5%, at time of 
inclusion into the cohort (2007–2010). Correspondingly 
for patients with T1D, 25% and 11% presented with HbA1c 
<7.0% and <6.5%, respectively. In this period, 37% (42% 
of T2D and 16% of T1D) were below the 99.9 percentile 
limit of 6.6% (Table 2). The percentage of patients reaching 
the recommended treatment targets for blood pressure and 
circulating levels of triglycerides, LDL, and HDL is visual-
ized in Table 3A, B. HbA1c <7%, systolic blood pressure, 
triglycerides, and LDL cholesterol are depicted in Figures 
3 and 4A–C.
In this Vejle cohort, 28% of the T2D patients achieved the 
treatment target for blood pressure (140/90 mmHg) compared 
with 48% in T1D patients (Table 4); 81% and 89% of T2D 
and T1D patients, respectively, were treated with at least 
an ACE-inhibitor or AT2 antagonist, whereas only 50% of 
the control population treated with antihypertensive agents 
received an ACE-inhibitor or AT2 antagonist.
Of the 2,721 patients with T2D, 74% were treated with 
cholesterol-lowering agents, and among the T2D patients aged 
≥40 years, 74% received statins. However, the percentage of 
Table 2 Number and percentage of subjects in each group reaching stated criteria for HbA1c
Population (N) HbA1c <6.5% (48 mmol/mol)
% (n/population na)
HbA1c <6.6%
(48.6 mmol/mol)
% (n/population na)
HbA1c <7.0% 
(53 mmol/mol)
% (n/population na)
HbA1c £7.5% 
(58 mmol/mol)
% (n/population na)
T2D (2,721) 32 (858/2,710) 42 (1,132/2,710) 56 (1,514/2,710) 75 (2,037/2,710)
T1D (599) 11 (68/597) 16 (97/597) 25 (147/597) 46 (277/597)
Controls (4,255) 98 (4,185/4,251) 99 (4,206/4,251) 99 (4,226/4,251) 100 (4,237/4,251)
Note: aPopulation n: Population (N) minus missing values.
Abbreviations: T1D, type 1 diabetes; T2D, type 2 diabetes; HbA1c, glycated hemoglobin.
Table 3A Percentage and number of females fulfilling the stated key criteria
Population, 
women (N)
Systolic blood pressure 
<140 mmHg
% (n/ population na)
Diastolic blood 
pressure <90 mmHg
% (n/population na)
Triglycerides <1.7 
mmol/L
% (n/population na)
LDL <2.6 mmol/L % 
(n/population na)
HDL ≥1.3 mmol/L
% (n/population na)
T2D (1,052) 39 (403/1,040) 71 (734/1,040) 56 (591/1,047) 68 (713/1,047) 57 (594/1,047)
T1D (234) 60 (139/231) 85 (197/231) 90 (210/234) 69 (161/234) 86 (202/234)
Controls (1,873) 58 (1,079/1,859) 73 (1,350/1,859) 86 (1,606/1,868) 27 (498/1,868) 85 (1,578/1,868)
Note: aPopulation n: Population (N) minus missing values.
Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; T1D, type 1 diabetes; T2D, type 2 diabetes.
Table 3B Percentage and number of males fulfilling the stated key criteria
Population, men (N) Systolic blood 
pressure  
<140 mmHg
% (n/population na)
Diastolic blood 
pressure  
<90 mmHg
% (n/population na)
Triglycerides  
<1.7 mmol/L
% (n/population na)
LDL <2.6 mmol/L
% (n/population na)
HDL ≥1.0 mmol/L
% (n/population na)
T2D (1,669) 29 (473/1,652) 62 (1,027/1,650) 60 (994/1,665) 69 (1,152/1,665) 72 (1,205/1,665)
T1D (365) 46 (164/358) 75 (268/358) 85 (309/365) 67 (244/365) 91 (331/365)
Controls (2,382) 36 (860/2,365) 54 (1,267/2,365) 76 (1,809/2,374) 24 (581/2,374) 90 (2,135/2,374)
Note: aPopulation n: Population (N) minus missing values.
Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; T1D, type 1 diabetes; T2D, type 2 diabetes.
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Figure 3 HbA1c: Cumulative percentage of individuals and HbA1c (%), females and males, respectively, in T2D patients (solid curve), T1D patients (dotted curve), and 
control individuals (dot-dash curve). Vertical solid line: HbA1c =7%.
Abbreviations: DCCT, Diabetes Control and Complication Trial; T1D: type 1 diabetes; T2D: type 2 diabetes; HbA1c, glycated hemoglobin.
Females Males
Control T1D T2D
100%
75%
50%
25%
0%
4 6 8 10 12 4 6 8 10 12
HbA1c (DCCT %)
Figure 4 (A) Cumulative percentage of individuals and systolic blood pressure (mmHg), females and males, respectively, in T2D patients (solid curve), T1D patients (dotted 
curve) and control individuals (dot-dash curve). Vertical solid line: systolic blood pressure =140 mmHg. (B) Cumulative percentage of individuals and triglycerides (mmol/L), 
females and males, respectively, in T2D patients (solid curve), T1D patients (dotted curve), and control individuals (dot-dash curve). Vertical solid line: triglycerides =1.7 
mmol/L. (C) Cumulative percentage of individuals and LDL (mmol/L), females and males, respectively, in T2D patients (solid curve), T1D patients (dotted curve), and control 
individuals (dot-dash curve). Vertical solid line: LDL =2.6 mmol/L.
Abbreviations: LDL, low density lipoprotein; T1D, type 1 diabetes; T2D, type 2 diabetes.
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T2D patients aged ≥40 years having a serum total cholesterol 
>4.5 mmol/L and not being treated with statins was 44% 
(Table 5). Thirty-four percent of the T2D and 55% of the 
T1D patients met treatment targets for serum lipids (Table 4).
Discussion
Behind the idea of establishing the Vejle Diabetes Biobank 
was an intention to increase the etiological knowledge about 
T2D and its comorbidities and to enhance the quality of dia-
betes care on the population level as well as for the individual 
patient. Along with the expanding genetic knowledge and the 
economic restriction in most healthcare systems, there has 
been a growing demand for individually precision tailored 
and targeted intervention. Biorepositories are in this regard 
most valuable resources as they allow for investigation of 
etiologies and intermediate, predictive, and prognostic bio-
markers of disease of interest as well as of comorbidities; 
hence, new analytical tests with potential predictive value 
for diabetes or its related complications can be tested before 
being used prospectively.30
The strength of the Vejle Diabetes Biobank is its 
 well-characterized individuals, completeness, and extent of 
laboratory, genetic, and anthropometric variables. This pro-
vides valuable data on modifiable lifestyle cardiovascular risk 
factors as body weight, BMI, blood pressure, smoking status, 
and physical activity. The possibility of linkage between the 
cohort and various Danish national population registries 
(eg, the Danish National Patient Registry, the Danish Civil 
Registration System and the Danish National Prescription 
Registry) gives access to consecutive information on the 
diabetes prognosis. The Vejle Diabetes Biobank represents 
one of the largest diabetes case-control cohorts in Denmark 
sampled from the same geographic area. Another biobank, 
the nationwide Danish Diabetes DD2 cohort, has since 
spring 2011 systematically collected and stored blood, urine, 
and obtained questionnaires from newly diagnosed T2D 
patients.31–33 This gives unique follow-up possibilities from 
time of diagnosis, but only ~5% of incident T2D patients per 
year are enrolled in the DD2 cohort30 making the risk of selec-
tion bias substantially high. Further, the DD2 has no control 
cohort. In the Vejle Diabetes Biobank, both the diabetes and 
the control population show a response rate of 39%–40%. 
This is a level corresponding to similar investigations based 
on voluntary participation.34
The limitation of the Vejle Diabetes Biobank is the lack 
of repeated sampling and repeated questionnaires over time, 
thus limiting the laboratory data and anthropometrics to the 
time of entry into the cohort. This can however partly be 
compensated by the ability to search clinical and laboratory 
data covering all patients in the region, and stored in national 
accessible registries. Further, the study is limited by the fact 
that the study participants have not been followed from their 
birth or the time of diagnosis and delayed entry will bias all 
attempts on absolute mortality estimation.35
As previously demonstrated,36 only 8% in 1993 and 22% 
in 2001 of patients with diabetes in the Vejle County had 
HbA1c below the 99.9 percentile limit of 6.6% (48.6 mmol/
mol). In 2007–2010, 37% (42% of patients with T2D and 
16% patients with T1D) were below the 6.6% limit, which 
is a significant increase in percentage of diabetes patients 
achieving glycemic regulation (HbA1c) below 6.6% of 29 
and 15 percentage points, respectively. The former statistics 
was performed on the basis of all HbA1c measures available 
Table 4 Percentage and number of subjects fulfilling the stated criteria
Population (n) Blood pressure  
<140/90 mmHg
% (n/population na)
Lipids (LDL, HDL, 
triglyceridesb)
% (n/population na)
Treated with ACE-inhibitors or AT2-
antagonists
% (n/population na being treated with 
antihypertensive agentsa)
Aged ≥40 years and 
treated with statins
% (n)
T2D (2,721) 28 (745/2,690) 34 (910/2,712) 81 (1,738/2,136) 74 (1,983)
T1D (599) 48 (284/589) 55 (327/597) 89 (292/329) 63 (295)
Controls (4,255) 40 (1,699/4,222) 20 (844/4,240) 50 (589/1,172) 17 (690)
Notes: aPopulation n: Population (N) minus missing values, bLDL <2.6 mmol/L, triglycerides <1.7 mmol/L, HDL ≥1 mmol/L in men/ HDL ≥1.3 mmol/L in women.
Abbreviations: ACE, angiotensin-converting-enzyme inhibitors; AT2, angiotensin 2 receptor antagonist; HDL, high density lipoprotein; LDL, low density lipoprotein; T1D, 
type 1 diabetes; T2D, type 2 diabetes.
Table 5 Highlights of findings for T2D and T1D patients
Facts for T2D: 
56% reach HbA1c <7.0% (53 mmol/mol)
28% reach blood pressure <140/90 mmHg
34% meet treatment target for lipids
44% of patients with total cholesterol >4.5 mmol/L are not treated with 
statins 
Facts for T1D:
25% reach HbA1c <7.0% (53 mmol/mol)
48% reach blood pressure <140/90 mmHg
55% meet treatment target for lipids
44% of patients with total cholesterol >4.5 mmol/L are not treated with 
statins
Abbreviations: T1D, type 1 diabetes; T2D, type 2 diabetes; HbA1c, glycated 
hemoglobin.
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in the laboratory database in the Vejle County from both 
hospitals and primary care centers, counting both T2D and 
T1D patients. In the present study, the statistics analyses 
were done only among the Vejle Diabetes Biobank par-
ticipants (40% responders). This fact might contribute to a 
better result due to the selection bias as it is well known that 
participants often are of better health and belong to a higher 
socioeconomic group than the nonparticipants.22 Consistent 
with this, the authors previously showed that participants 
in the Vejle Diabetes Biobank, both diabetic and control 
individuals, had a significantly lower number of registered 
diagnoses, ie, lower Charlson Comorbidity Index Score,37 
than their nonparticipant counterparts and demonstrated all 
over healthier biomarkers.38
Having improved diabetes care over the years by better 
glycemic regulation and increased focus on the importance 
of controlling the patient’s cardiovascular risk factors39,40 
and modifying the lifestyle, there still seems to be room for 
improvement as only less than six out of ten T2D patients 
(56%) and only one out of four T1D patients (25%) in this 
cohort (2007–2010) fulfilled the international consensus 
treatment goals of HbA1c <7%. Nationally, 70% of T2D 
and 44% of T1D patients achieved a glycemic level at or 
under 7.5% in 2014–2015;41 in this cohort, the correspond-
ing numbers were 75% and 46%, respectively (Table 2), thus 
slightly better than the reported present national average.41
In Germany, a significant improvement of 33 percentage 
points in glycemic regulation over a 10-year time period was 
observed among a cohort of T2D patients, as 32% of the 
patients in 1997–1999 (n=333) versus 65% in 2008–2011 
(n=526) had an HbA1c <7%,42 thus a superior result com-
pared to what the authors found.
Only 28% of the T2D patients achieved treatment target 
for blood pressure (140/90 mmHg) compared with 48% in 
T1D patients. In this cohort, 81% and 89% of T2D and T1D 
patients, respectively, were treated with ACE-inhibitors or AT2 
antagonists, thus fulfilling the guidelines on anti-hypertensive 
treatment in which the first choice is either an ACE-inhibitor 
or AT2 antagonist. Of the T2D patients aged 40 years or more, 
74% were treated with lipid-lowering agents; still, 44% of 
diabetes patients having total cholesterol values >4.5 mmol/L 
were not treated with statins and only 34% of the T2D patients 
met the treatment target for lipids. Today, increased awareness 
of the importance of controlling the patients’ cardiovascular 
risk factors may lead to more extended use of lipid-lowering 
agents and more intensive use of antihypertensive treatment, 
thereby reducing diabetes related cardiovascular morbidity 
and mortality.43,44 Even so, the Guidance study45 found scope 
for further improvement in diabetes care (HbA1c, blood pres-
sure, and LDL) in eight European countries.
At present, the Vejle Diabetes Biobank has led to vari-
ous publications in the field of diabetes, metabolism, and 
genetics16,38,46–57 and is continuously an open resource for 
international and national researchers. Thus, all research 
groups are invited to contact the authors and present their 
scientific hypotheses on a collaborative basis to have access 
to biological materials and available clinical data.
Data access
Data on biomarkers in anonymized form can be accessed at 
http://dda.dk/catalogue/19269?lang=en
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Supplementary material
Information for patients
We kindly ask you to participate in the study: “Biobank for diabetes”.
“Biobank for diabetes”
The prevalence of diabetes has increased during the last years, particularly the type 2 diabetes. Genetic inheritance and 
environmental factors play a role for the development of type 2 diabetes. The aim of this study is:
1. To establish a biobank with blood samples and urine samples from 6,000 patients with diabetes and 6,000 persons 
without diabetes (control persons). The collection of data will last for 2–3 years.
2. To identify biochemical and molecular markers in blood and urine samples.
3. To compare the results of diabetes patients and control persons.
4. Hopefully to find the differences in lifestyle, environmental and inheritable factors, which causes diabetes and reduces 
lifetime due to diabetes-related complications.
5. To apply the knowledge in prevention and treatment of current and future patients.  
What are the procedures on the day of examination, when you choose to register in the Biobank?
•	 You only have to meet up once. You can choose Vejle, Kolding, Fredericia, or Horsens Hospital.
•	 The examination will take place between 7.15 and 09.30 a.m. It will take about half an hour. Height, weight, waist 
and hip measurement, body fat percentage, blood pressure and blood glucose will be recorded, and you will get a 
copy of the data.
•	 A number of samples will be taken for storage in the Biobank (all together about 125 mL blood).
•	 Before the day of examination you will receive a container for the urine sample, please bring the urine sample on the 
day of examination.
•	 Before the examination you will also receive a questionnaire about tobacco, alcohol, exercise etc. Please bring this 
as well on the day of examination.
•	 After the examination you are offered some breakfast and coffee or tea. (If you need to take any medication, it will 
be possible at this time).
What to remember on the day of examination when registering in the Biobank:
•	 Please fast overnight, i.e. no eating, drinking (coffee, tea, milk, alcohol, juice etc.) or smoking from 10 p.m. the day 
before the examination. You are allowed 1–2 glasses of water from 10.00 p.m. until the examination takes place. 
•	 Please do not take medication for blood glucose regulation (insulin or tablets). This morning please try to avoid tak-
ing medication unless absolutely necessary until the examination has finished.
•	 Please do not run or ride a bike on the day of examination.
•	 Please remember to bring the urine sample mentioned above.
•	 Please remember to bring the questionnaire mentioned above.
•	 Moreover, you should live and eat as usually the last 3 days before examination.
What are the disadvantages/risks from participating in the study?
There is no physical risk or side effects from participating. The blood sampling might cause some temporary pain and bruise 
at the puncture site.
What are the advantages from participation in the study?
The study is expected to generate important information about the heritable differences in the Danish population causing 
diabetes and reducing the life span because of insufficient effect of the medical treatment and diabetes-related compli-
cations. Therefore, the study is useful in preventing new cases of diabetes and improving treatment for future diabetes 
patients.
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The study might be able show if you belong to a group with higher risk of diabetes-related complications and therefore 
might have an extended need for treatment to avoid complications and premature death.
Can you be excluded from the study?
No, only if you choose to.
The study can be stopped if the funding discontinues. In that case all biological samples and data will be destructed.
Economy
The study was funded by the Danish Council for Independent Research/Medical Sciences, the Research Council of Vejle 
Hospital, the Department of Internal Medicine, Vejle Hospital, Vejle County, and the Danish Research Fund. The budget 
is 12 million DDK.
Your participation in the study is completely voluntary. You can withdraw your consent at any time. The paper: “The 
rights of a trial subject in a biomedical research project” is attached. It is elaborated by the National Committee for Health 
Research Ethics.
If you have any questions, you are welcome to contact the doctors.
Sincerely,
Project manager Clinical responsible
Ivan Brandslund Cramer Christensen
Laboratory director, dr. med, MD Consultant, dr. med, MD
Laboratory, Department of Clinical Biochemistry Department of Internal Medicine
Vejle Hospital Vejle Hospital
Tel: 7 940 6500 Tel: 7 940 6306
Declaration of consent
For the study:
“Biobank for diabetes”
The aim of the study is to establish a biobank with samples of blood and urine, stored frozen for subsequent research. Do 
you permit that your blood and urine samples are collected in the biobank and subsequently used for identifying biochemical 
and heritable markers? (Please mark with a cross)
Yes____ No_____
In this study we might find out that certain persons have specific changes in the biochemical markers increasing the risk for 
complications to diabetes (e.g. thrombus in the heart, diabetic eye disorder, or calcification).
If assuming that we can improve the treatment of your diabetes, do you want to get information about the findings in 
your particular blood samples? (Please mark with a cross)
Yes____ No_____
You can change your decision about this information anytime by contacting:
Laboratory, Department of Clinical Biochemistry
Vejle Hospital
Kabbeltoft 25
7100 Vejle
Tel: 7 940 6506
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To be completed in the laboratory on the day of examination 
“I hereby declare that I – given the information above orally and written – consent to participate in the former 
described study. I am informed that participation is voluntary and that I can withdraw my consent anytime.”  
Date: _____________ Name of the participant (please use capital letters) and CPR no: 
______________________________________________________________________________________________
Signature of the participant: _______________________________________________________________________
Name and signature of the clinician informing the participant: _____ ___________ ____________________________
______________________________________________________________________________________________
Signature of the responsible doctor: _________________________________________________________________
If you have questions to the above, please contact: 
Project manager Clinical responsible
Ivan Brandslund Cramer Christensen
Laboratory director, dr. med, MD Consultant, dr. med, MD
Department of Clinical Chemistry Department of Internal Medicine
Vejle Hospital, Tel: 7 940 6500 Vejle Hospital, Tel: 7 940 6306
Attachment 3: Questionnaire for patients
To be filled in by the laboratory: 
Date: ________________________
The patient is fasting, e.g. no intake of food nor medication for blood glucose regulation
(Please mark with a cross)  Yes _____ No ______                     Other medication   Yes_____ No______
Height without shoes (cm) _______ Weight without shoes (kg) ____________ Fat %__________ (measured without 
stocking).
Fat mass (kg) __________Fat-free mass (kg) __________Total amount of body fluid (kg) __________
Waist (cm) ____________ (measured directly on the skin)  
Hip (cm) ___________ (measured outside clothes) 
Blood pressure (mmHg) ________________________________________ (after 5 min of rest)
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To be filled in by the laboratory: 
Name: __________________________________________________________________________________________
CPR no: __________________________________________________________________________________________
Address: _________________________________City code:__________City:___________________________________
Tel: ___________________ Cell phone:_________________________________________________________________
Sex:           Male                 Female                                           Age: _______________________________________
Do you have diabetes type     1                     2                     Age at onset of disease: __________________________ 
Do you get insulin treatment?  Yes              No           
If yes, your age by the start of insulin treatment: ____   Name of the drug: _____________________________________
Do you smoke?    Daily             Occasionally                 Ex-smoker               Never smoked
Alcohol consumption:      None              Occasionally                         1–7 units/week            
7–14 units/week              14–21   units/week                  More than 21 units/week            
Do you exercise?   Yes                      No
If yes, how many times a week_________     Duration per exercise (minutes) _________
Intensity:   Low                   (e.g. walking, gardening, etc.)            
  Moderate           (e.g. cycling, quick walking, etc.)   
  High                  (e.g. spinning, badminton, running, etc.)
Gestational diabetes (question for women)
Number of pregnancies: _____________________ 
Gestational diabetes      Yes             No                     First gestational diabetes (Year):_____________
Do you have/did you have complications to diabetes in: 
1) Eyes (have you had a laser treatment):  Yes                          No                  Don’t know                  
2) Kidney:     Yes                          No                  Don’t know                  
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3) Nerves (neuritis in the legs):               Yes                          No                  Don’t know     
4) Feet (wounds): Yes                  No              Don’t know    
 If Yes:      Current                 Previous           
 Do you have/did you have a disease in: (please mark with a cross)
1) Heart (e.g. thrombus in the heart, heart pain, etc.)         Yes                  No   
If yes, please note the diseases: __________________________________________
______________________________________________________________________
Do you use a pacemaker: Yes                No    
2) Brain (e.g. thrombus, brain hemorrhage):      Yes                         No    
If yes, please write the diseases: ____________________________________________
3) Poor circulation of blood in the legs:       Yes    No                Don’t know     
4) Other diseases:     Yes          No   
If yes, please note the diseases: ___________________________________________
________________________________________________________________________
Do you take any medications?        Yes                No    
If yes, please fill in the blanket using capital letters:
Name of the 
drug
How many mg/mL 
etc. per tablet
Number of tablets
Morning Noon Evening Night
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Questions of inheritance
Is/was your mother Danish?           Yes                       No                      Don’t know     
If not, please note the nationality: _______________________
Is/was your father Danish?              Yes                       No                     Don’t know     
If not, please note the nationality: _______________________
Is/was your maternal grandmother Danish?          Yes                 No                 Don’t know     
If not, please note the nationality: _______________________
Is/was your maternal grandfather Danish?          Yes                    No                 Don’t know     
If not, please note the nationality: _______________________
Is/was your paternal grandmother Danish?         Yes             No               Don’t know      
If not, please note the nationality: _______________________
Is/was your paternal grandfather Danish?          Yes             No              Don’t know      
If not, please note the nationality: _______________________
Only fill in, if the family member is/was diagnosed with diabetes
Please write the year, or mark with a cross. If you doubt whether to mark “yes” or “no” please write “don’t know” 
or “?”
Parents Age when 
diagnosed
Diet/ regimen Tablets Insulin Age by start of insu-
lin treatment
Yes No Yes No Yes no
Mother
Father
Siblings Age when 
diagnosed
Diet/ regimen Tablets Insulin Age by start of 
insulin treatment
Yes No Yes No Yes no
S1:
S2:
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Vejle Diabetes Biobank – study design
S3:
S4:
S5:
S6:
S7:
Children Age when 
diagnosed
Diet/regimen Tablets Insulin Age by start of 
insulin treatment 
Yes No Yes No Yes no
B1:
B2:
B3:
B4:
B5:
B6:
B7:
Other family member diagnosed with diabetes (e.g. uncle, aunt, grandparents, etc.)
Family
member
Age when 
diagnosed
Diet/regimen Tablets Insulin Age by start of 
insulin treatment 
Yes No Yes No Yes no
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